Pasi A. Jänne, MD, PhD

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, notes that in the phase 3 REZILIENT3 trial, presented at the 2026 World Conference on Lung Cancer, adding zipalertinib to chemotherapy extended progression-free survival (PFS) by 6 months in first-line EGFR exon 20 insertion–mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, asks Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, how to weigh PAPILLON against WU-KONG28 in first-line EGFR exon 20 insertion–mutated non–small cell lung cancer without a head-to-head trial.

Pasi A. Jänne, MD, PhD, and Yi-Long Wu, MD, FACS, compare first-line EGFR-mutated NSCLC care in the US and China and discuss SAFFRON and SANOVO.

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, reviews the phase 3 WU-KONG28 trial of first-line sunvozertinib vs carboplatin plus pemetrexed in untreated EGFR exon 20 insertion–mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, reviews the phase 3 PAPILLON trial, which established amivantamab, a bispecific EGFR-MET antibody, plus chemotherapy as first-line standard of care for EGFR exon 20 insertion–mutated non–small cell lung cancer, with a median progression-free survival of 11.4 vs 6.7 months with chemotherapy.

Exon 20 EGFR insertions often go misreported, driving suboptimal inhibitor use; experts explain why NGS and liquid testing improve lung cancer treatment choices.

Explore evolving first- and later-line treatments for EGFR exon 20 insertion NSCLC, including new targeted agents, chemo combos, and mutation-specific research.

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

Pasi A. Jänne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Pasi A. Jänne, MD, PhD, discusses key findings from the primary analysis of the phase 2 DESTINY-Lung02 trial in patients with HER2-mutant non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.